A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (Microbiota Suspension) in Subjects with Recurrent Clostridium difficile Infection (Protocol # 2019-01)

Grants and Contracts Details

StatusFinished
Effective start/end date10/24/19 → 4/5/22

Funding

  • Rebiotix Inc: $9,500.00